These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 31513248)
41. Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials. Moretto R; Vetere G; Carullo M; Ciracì P; Masi G; Cremolini C Cancer Treat Rev; 2024 Nov; 130():102829. PubMed ID: 39305700 [TBL] [Abstract][Full Text] [Related]
42. Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. Kotaka M; Yamanaka T; Yoshino T; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Nakamura F; Bando H; Taniguchi H; Gamoh M; Shiozawa M; Saji S; Maehara Y; Mizushima T; Ohtsu A; Mori M ESMO Open; 2018; 3(3):e000354. PubMed ID: 29713499 [TBL] [Abstract][Full Text] [Related]
43. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. Loree JM; Sha A; Soleimani M; Kennecke HF; Ho MY; Cheung WY; Mulder KE; Abadi S; Spratlin JL; Gill S Clin Colorectal Cancer; 2018 Jun; 17(2):156-163. PubMed ID: 29486916 [TBL] [Abstract][Full Text] [Related]
44. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362 [TBL] [Abstract][Full Text] [Related]
46. A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer. Margalit O; Mamtani R; Yang YX; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B Eur J Cancer; 2018 Jun; 96():105-110. PubMed ID: 29698932 [TBL] [Abstract][Full Text] [Related]
47. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience. Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288 [TBL] [Abstract][Full Text] [Related]
48. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. Wagner AD; Grothey A; Andre T; Dixon JG; Wolmark N; Haller DG; Allegra CJ; de Gramont A; VanCutsem E; Alberts SR; George TJ; O'Connell MJ; Twelves C; Taieb J; Saltz LB; Blanke CD; Francini E; Kerr R; Yothers G; Seitz JF; Marsoni S; Goldberg RM; Shi Q J Natl Cancer Inst; 2021 Apr; 113(4):400-407. PubMed ID: 32835356 [TBL] [Abstract][Full Text] [Related]
49. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334 [TBL] [Abstract][Full Text] [Related]
50. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198 [TBL] [Abstract][Full Text] [Related]
51. The Course of Neuropathic Symptoms in Relation to Adjuvant Chemotherapy Among Elderly Patients With Stage III Colon Cancer: A Longitudinal Study. van Erning FN; Janssen-Heijnen MLG; Wegdam JA; Slooter GD; Wijsman JH; Vreugenhil A; Beijers TAJM; van de Poll-Franse LV; Lemmens VEPP Clin Colorectal Cancer; 2017 Sep; 16(3):195-203. PubMed ID: 27756521 [TBL] [Abstract][Full Text] [Related]
52. Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice? Formica V; Zaniboni A; Loupakis F; Roselli M Int J Cancer; 2018 Nov; 143(10):2342-2350. PubMed ID: 29873066 [TBL] [Abstract][Full Text] [Related]
53. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial. Avallone A; Piccirillo MC; Nasti G; Rosati G; Carlomagno C; Di Gennaro E; Romano C; Tatangelo F; Granata V; Cassata A; Silvestro L; De Stefano A; Aloj L; Vicario V; Nappi A; Leone A; Bilancia D; Arenare L; Petrillo A; Lastoria S; Gallo C; Botti G; Delrio P; Izzo F; Perrone F; Budillon A JAMA Netw Open; 2021 Jul; 4(7):e2118475. PubMed ID: 34309665 [TBL] [Abstract][Full Text] [Related]
54. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. André T; Boni C; Navarro M; Tabernero J; Hickish T; Topham C; Bonetti A; Clingan P; Bridgewater J; Rivera F; de Gramont A J Clin Oncol; 2009 Jul; 27(19):3109-16. PubMed ID: 19451431 [TBL] [Abstract][Full Text] [Related]
55. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539 [TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. Rosati G; Lonardi S; Galli F; Di Bartolomeo M; Ronzoni M; Zampino MG; Banzi M; Zaniboni A; Pasini F; Bozzarelli S; Garattini SK; Ferrari D; Montesarchio V; Mambrini A; Ciuffreda L; Galli F; Pusceddu V; Carlomagno C; Bidoli P; Amoroso D; Bochicchio AM; Frassineti L; Corsi D; Bilancia D; Pastorino A; De Stefano A; Labianca R; Eur J Cancer; 2021 May; 148():190-201. PubMed ID: 33744715 [TBL] [Abstract][Full Text] [Related]
57. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis. Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875 [TBL] [Abstract][Full Text] [Related]